TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

AZMIRO

TESTOSTERONE CYPIONATE
Oncology Approved 2022-06-02
1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Prescription
First Approved
2022-06-02
Routes
INTRAMUSCULAR
Dosage Forms
SOLUTION

Companies

Active Ingredient: TESTOSTERONE CYPIONATE

AZMIRO Approval History

Loading approval history...

What AZMIRO Treats

1 indications

AZMIRO is approved for 1 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypogonadism
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AZMIRO FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

1 INDICATIONS & USAGE AZMIRO is indicated for testosterone replacement therapy in males in conditions associated with a deficiency or absence of endogenous testosterone: β€’ Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchiectomy, Klinefelter’s syndrome, or toxic damage from alcohol or heavy metals, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone (FSH), lu...

AZMIRO Patents & Exclusivity

Latest Patent: Mar 2039

Patents (3 active)

US12138271 Expires Mar 25, 2039
US11642355 Expires Mar 25, 2039
US11311554 Expires Mar 25, 2039
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.